Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ketoconazole: a reappraisal.

Literature DB >> 3917777

Ketoconazole: a reappraisal.

R J Hay.

Abstract

Entities: Chemical

Mesh：

Substances：
Ketoconazole

Year: 1985 PMID： 3917777 PMCID： PMC1417545 DOI： 10.1136/bmj.290.6464.260

Source DB: PubMed Journal: Br Med J (Clin Res Ed) ISSN： 0267-0623

× No keyword cloud information.

13 in total

1. Toxic hepatis during ketoconazole treatment.

Authors: J K Heiberg; E Svejgaard
Journal: Br Med J (Clin Res Ed) Date: 1981-09-26

2. The treatment of patients with chronic mucocutaneous candidosis and candida onychomycosis with ketoconazole.

Authors: R J Hay; Y M Clayton
Journal: Clin Exp Dermatol Date: 1982-03 Impact factor: 3.470

3. A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize.

Authors: N Zaias; D Drachman
Journal: J Am Acad Dermatol Date: 1983-12 Impact factor: 11.527

4. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.

Authors: I M Hann; H G Prentice; R Corringham; H A Blacklock; M Keaney; M Shannon; P Noone; E Gascoigne; J Fox; E Boesen; M Szawatkowski; A V Hoffbrand
Journal: Lancet Date: 1982-04-10 Impact factor: 79.321

5. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses.

Authors: E Drouhet; B Dupont
Journal: Am J Med Date: 1983-01-24 Impact factor: 4.965

6. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

Authors: W E Dismukes; A M Stamm; J R Graybill; P C Craven; D A Stevens; R L Stiller; G A Sarosi; G Medoff; C R Gregg; H A Gallis; B T Fields; R L Marier; T A Kerkering; L G Kaplowitz; G Cloud; C Bowles; S Shadomy
Journal: Ann Intern Med Date: 1983-01 Impact factor: 25.391

7. Ketoconazole in griseofulvin-resistant dermatophytosis.

Authors: M H Robertson; P Rich; F Parker; J M Hanifin
Journal: J Am Acad Dermatol Date: 1982-02 Impact factor: 11.527

8. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors: M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal: N Engl J Med Date: 1981-12-10 Impact factor: 91.245

Ketoconazole: a reappraisal.

1. Toxic hepatis during ketoconazole treatment.

2. The treatment of patients with chronic mucocutaneous candidosis and candida onychomycosis with ketoconazole.

3. A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize.

4. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.

5. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses.

6. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

7. Ketoconazole in griseofulvin-resistant dermatophytosis.

8. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

9. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.

10. Gynecomastia with ketoconazole.

1. Purification and properties of cytochrome P-450-dependent 14 alpha-sterol demethylase from Candida albicans.

2. Clotrimazole pessary compared with cream in treating women with vaginal candidosis.

3. Control of an outbreak of systemic Candida albicans.

4. Intermittent local prophylaxis against recurrent vaginal candidosis.

Review 5. Clinical pharmacokinetics of ketoconazole.

6. Four outbreaks of nosocomial systemic candidiasis.